Tokyo, Sept. 24 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059171) titled 'Correlation Between Non-Perfusion Areas and Retinal Sensitivity in Diabetic Macular Edema Resolved After Anti-VEGF Therapy' on Sept. 24.
Study Type:
Observational
Primary Sponsor:
Institute - university of Fukui Hospital
Condition:
Condition - diabetic retinopathy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the relationship between retinal ischemia and sensitivity in patients with diabetic macular edema (DME) who achieved edema remission through anti-VEGF treatment.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with diabetic retinopathy who had previously received anti-VEGF drug treatment for diabetic macular edema at each research institution within the period up to the date of ethics committee approval, and who have not experienced recurrence of edema for six months without anti-VEGF drug treatment, and who underwent visual field measurement using OCTA and Humphrey perimeter.
There are no restrictions on other DME treatments, such as anti-VEGF drugs or laser therapy.
Key exclusion criteria - 1. Patients who declined to participate in this study
2. Patients with retinal diseases other than DME (e.g., retinal vein occlusion)
3. Patients with neovascular glaucoma
Target Size - 40
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2024 Year 09 Month 19 Day
Date of IRB - 2024 Year 09 Month 19 Day
Anticipated trial start date - 2024 Year 09 Month 19 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067628
Disclaimer: Curated by HT Syndication.
